Discovery and development of an endothelin A receptor-selective antagonist PD 156707.
PD 156707 is a highly potent, selective antagonist of the ETA receptor that has demonstrated efficacy in a number of different disease models. The next few years will be exciting in the field of ET research as several compounds progress through clinical development. It is our hope that the efficacy that data demonstrated to date with PD 156707 will some day be translated into real hope for the patients who are waiting beyond the confines of our research laboratories.
Department of Chemistry, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
A M
AM
Doherty
A C
AC
Uprichard
D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D004149:Dioxoles / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D044022:Receptor, Endothelin A; D013329:Structure-Activity Relationship
D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; C093321:PD 156707; D044022:Receptor, Endothelin A